With shares languishing near $5.74, Bausch Health Companies (BHC) presents a stark valuation puzzle. While a standard DCF model suggests a staggering 91% undervaluation, the market's persistent sell-off reflects deep-seated concerns over the company's restructuring path and debt burden. We examine the numbers behind the divergence.
India is negotiating with Ant International to link its Unified Payments Interface (UPI) with the Alipay+ network, a move that could simplify overseas transactions for Indian travelers and signal a thaw in economic relations with China, according to government sources.
Standex International Corporation (NYSE: SXI) capped off its fiscal 2025 with a powerful fourth quarter, announcing record adjusted operating margins of 20.6% and laying out an ambitious roadmap for over $100 million in revenue growth for the coming year. CEO David Dunbar declared a "turning point" for the diversified industrial manufacturer, citing scaled growth drivers in electronics, engineering technologies, and fast-growing markets like grid modernization and defense.
Analysts at Susquehanna upgrade Arm Holdings to Positive, citing transformative deals with OpenAI and Meta. The firm projects a new AI XPU could generate over $1 billion in annual royalties, signaling a major shift beyond Arm's mobile roots.
President Gustavo Petro's suggestion that Jesus Christ had a romantic relationship with Mary Magdalene has drawn sharp criticism from religious groups and believers, igniting a heated debate about the boundaries between political speech and religious respect in the predominantly Christian nation.
The stablecoin issuer finished 2025 with over $10 billion in net profit, backed by a $17.4 billion gold reserve and a U.S. Treasury portfolio that rivals major nations, as demand for its USDT token continues to surge globally.
As Palantir Technologies prepares to report Q4 results, options markets signal significant volatility ahead, with the stock's AI-driven rally facing a reality check amid shifting investor focus.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
Despite a mixed analyst outlook, Morgan Stanley projects robust growth for Full Truck Alliance's core commission business, even as overall revenue faces headwinds. The digital freight platform's long-term strategy is gaining favor.
As OpenAI accelerates toward a potential year-end IPO, Amazon, Microsoft, and Nvidia are in advanced talks to lead a funding round that could exceed $100 billion, reshaping the AI industry's financial and competitive landscape.
Target is launching its largest-ever spring beauty collection, introducing over 3,000 new, predominantly budget-friendly items alongside redesigned in-store experiences and key leadership appointments, signaling a major strategic push to capture market share in the lucrative beauty sector.
In the wake of high-profile federal interventions and the killing of a nurse in Minneapolis, traditionally left-leaning demographics—including women, LGBTQ+ individuals, and people of color—are arming themselves at unprecedented rates, challenging long-held assumptions about American gun culture.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
Paramount Skydance is launching a new programmatic advertising platform for live sports on Paramount+ and initiating a quarterly dividend, signaling a strategic shift towards monetizing its existing audience amid ongoing financial pressures.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Despite a cautious 'Moderate Sell' consensus, Paramount Skydance (PSKY) carries an average price target of $14.08, implying significant potential upside. The media giant's recent Q3 2025 results highlighted robust Paramount+ subscriber growth, even as investors weigh heavy content investments and integration risks.
A major redevelopment of Newcastle University's Castle Leazes student village is moving forward, with contractor Bowmer + Kirkland appointed to deliver over 2,000 new affordable rooms, replacing 1960s-era facilities.
Brookfield Infrastructure Partners capped a strong 2025 with double-digit FFO growth, a record capital recycling program, and a raised distribution. Management highlighted a massive, disciplined expansion in data infrastructure to meet AI-driven demand, forecasting a return to 10%+ growth targets.
Advocate Health, the nation's third-largest nonprofit health system, is investing over $800 million in enhanced compensation and benefits for its 165,000+ employees, raising its minimum wage and expanding tuition aid, mental health support, and paid volunteer time.
After a recent pullback, shares of French construction materials giant Saint-Gobain are trading at a notable discount to analyst targets. While long-term performance remains robust, investors are weighing near-term risks against potential value.
